Loading...
Lee's Pharmaceutical Holdings Limited
0950.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$1.41
HK$-0.03(-2.08%)
Lee's Pharmaceutical Holdings Limited (0950.HK) Financial Performance & Statements
Review Lee's Pharmaceutical Holdings Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
32.95%
↑ 32.95%
Operating Income Growth
159.78%
↑ 159.78%
Net Income Growth
457.55%
↑ 457.55%
Operating Cash Flow Growth
119.85%
↑ 119.85%
Operating Margin
8.08%
↑ 8.08%
Gross Margin
53.81%
↑ 53.81%
Net Profit Margin
6.65%
↑ 6.65%
ROE
5.53%
↑ 5.53%
ROIC
6.13%
↑ 6.13%
Lee's Pharmaceutical Holdings Limited (0950.HK) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Lee's Pharmaceutical Holdings Limited stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $370.81M | $370.81M | $329.17M | $329.17M |
| Cost of Revenue | $169.43M | $169.43M | $153.88M | $153.88M |
| Gross Profit | $201.38M | $201.38M | $175.30M | $175.30M |
| Gross Profit Ratio | $0.54 | $0.54 | $0.53 | $0.53 |
| R&D Expenses | $24.88M | $24.88M | $17.04M | $17.04M |
| SG&A Expenses | $163.39M | $163.39M | $134.76M | $134.76M |
| Operating Expenses | $178.88M | $178.88M | $141.23M | $141.23M |
| Total Costs & Expenses | $348.31M | $348.31M | $295.11M | $295.11M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $23.64M | $35.23M | $35.23M | $35.23M |
| EBITDA | $56.89M | $68.48M | $68.75M | $68.75M |
| EBITDA Ratio | $0.15 | $0.18 | $0.21 | $0.21 |
| Operating Income | $22.50M | $22.50M | $34.07M | $34.07M |
| Operating Income Ratio | $0.06 | $0.06 | $0.10 | $0.10 |
| Other Income/Expenses (Net) | -$4.002M | -$4.002M | -$3.51M | -$3.51M |
| Income Before Tax | $18.50M | $18.50M | $30.55M | $30.55M |
| Income Before Tax Ratio | $0.05 | $0.05 | $0.09 | $0.09 |
| Income Tax Expense | $11.63M | $11.63M | $3.12M | $3.12M |
| Net Income | $15.31M | $15.31M | $31.24M | $31.24M |
| Net Income Ratio | $0.04 | $0.04 | $0.09 | $0.09 |
| EPS | $0.03 | $0.03 | $0.05 | $0.05 |
| Diluted EPS | $0.03 | $0.03 | $0.05 | $0.05 |
| Weighted Avg Shares Outstanding | $588.87M | $588.87M | $588.86M | $588.86M |
| Weighted Avg Shares Outstanding (Diluted) | $588.84M | $588.84M | $588.84M | $588.84M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan